Abrysvo

News

MSD preparing to take on Beyfortus with RSV antibody

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting

News

GSK gets EU okay for RSV shot in younger age group

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could l

News

MSD stakes claim to RSV prevention market for infants

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro

News

Moderna gets FDA okay for RSV vaccine mResvia

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax C

News

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al

News

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan

MSD preparing to take on Beyfortus with RSV antibody

GSK gets EU okay for RSV shot in younger age group

MSD stakes claim to RSV prevention market for infants

Moderna gets FDA okay for RSV vaccine mResvia

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Abrysvo

Editor's Picks